

## Amendments to the Specification:

Please add the following paragraph on page 1, line 3:


### Cross Reference to Related Applications

This application is the national stage of Application No. PCT/EP03/00276, filed January 13, 2003, which application claims priority from EPO Application No. 02075157.4, filed January 16, 2002.

## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (original) A compound of formula (I)



and stereochemically isomeric forms and pharmaceutically acceptable acid addition salts thereof.

Claim 2 (original) A compound as claimed in claim 1 having the cis configuration.

Claim 3 (original) A compound as claimed in claim 1 having the trans configuration.


Claim 4 (currently amended) A compound as claimed in [any of] claim[s] 1 [to 3] wherein the compound of formula (I) is the (1:1) hydrate.

Claim 5 (currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically active amount of a compound as claimed in [any of] claim[s] 1 [to 4].

Claim 6 (cancelled)

Claim 7 (cancelled)

Claim 8 (original) A process for preparing a compound of formula (I) by oxidizing a compound of formula (II) with a suitable oxidans in a reaction-inert solvent.



Claim 9 (new) A method for treating conditions involving motility disorders of the intestinal system or transit of the upper and lower gastrointestinal tract comprising administering to a host in need thereof an effective amount of a compound as claimed in claim 1.